Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AM109
- Development stage
- Preclinical
- Lead developer
- AbClon
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AM109 is a bispecific antibody therapeutic developed by AbClon for the treatment of intractable prostate cancer. Utilizing AbClon's proprietary AffiMab platform technology, AM109 is designed to simultaneously target Prostate-Specific Membrane Antigen (PSMA) on tumor cells and the costimulatory molecule 4-1BB (CD137) on T-cells. This dual-targeting approach is intended to induce T-cell activation specifically within the tumor microenvironment where PSMA is present, potentially enhancing efficacy while minimizing systemic immune-related adverse effects. The project was selected for the Korea Drug Development Fund (KDDF) national project in 2023 to support its advancement toward clinical trials.
- Other names
- AM109-AbClonAM-109-AbClonAM 109-AbClon
02
Targets
TNFRSF9 (CD137 extracellular domain)PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on AM109.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AM109.